Holen Sie sich die Stockscreener-App
26.58
1.04%
-0.28
Handel nachbörslich:
26.64
0.06
+0.23%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer Pipeline Updates Test Valuation Gap As New Trials Begin - simplywall.st
China Obesity Approval Puts Pfizer’s GLP 1 Bet In Sharper Focus - simplywall.st
Pfizer (PFE) Quietly Arms Pipeline for Next Growth Wave - TipRanks
Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data - TechStock²
Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation - Seeking Alpha
PFEPfizer Inc Stock Price and Quote - Finviz
Market Watch Rx: Pfizer Joins Top Gainers - Pharmaceutical Executive
Pfizer Targets Pediatric Ulcerative Colitis With New Etrasimod Trial: What Investors Should Watch - TipRanks
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart
Martingale Asset Management L P Has $12.88 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Arrowstreet Capital Limited Partnership Has $473.05 Million Stake in Pfizer Inc. $PFE - MarketBeat
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - Yahoo Finance
Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance Singapore
Pfizer (NYSE:PFE) Shares Down 1.7%Here's Why - MarketBeat
Pfizer's Top Legal Officer Nets Almost $2.3M More In 2025 - Law360
Lobbying Update: $2,870,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Self-represented worker’s 64-page Pfizer claim struck for violating pleading rules - HR Law Canada
CEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review - Pfizer
Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline - TipRanks
How Investors Are Reacting To Pfizer (PFE) Phase 2 Win For Tilrekimig In Atopic Dermatitis - simplywall.st
Form DEF 14A PFIZER INC For: Apr 23 - StreetInsider
The Best Covered Call Strategy to Trade High-Yielding Pfizer Stock and Earn Extra Income - Barchart.com
Franklin Resources Inc. Raises Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Mackenzie Financial Corp Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Capital World Investors Purchases 286,493 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer’s Weight Management Drug Wins China Approval - Insider Monkey
Pfizer, Teva lose bid to disqualify ex-prosecutor in generic drug price‑fixing case - Reuters
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
Pfizer streamlines LC/UV/MS data processing, analysis and reporting - Chromatography Today
Improving method transfer: How Pfizer uses method development software - Chromatography Today
Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study - TipRanks
Dilated Cardiomyopathy Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Bristol Myers Squibb, Berlin Cures, Cumberland Pharma, Vericel Corp, Corimmun GmbH, Pfizer, Constant Therapeut - Barchart.com
One Pediatric Gastroenterologist’s Mission to Expand Pediatric Treatment Options - Pfizer
651,996 Shares in Pfizer Inc. $PFE Bought by Kepler Cheuvreux Suisse SA - MarketBeat
Nasal Vaccines Market Is Going to Boom Rapidly | Pfizer • Moderna • GlaxoSmithKline - openPR.com
Richard Bernstein Advisors LLC Has $1.33 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc.: No turn-around in sight - marketscreener.com
Pfizer Stock: Cheap For A Reason (NYSE:PFE) - Seeking Alpha
Pfizer’s Comirnaty update: what the new COVID shot really means for you - AD HOC NEWS
Does Pfizer (PFE) Offer Value After Post Pandemic Pipeline And Patent Concerns - Yahoo Finance
Pfizer Tariff Exemptions And US$70b Pledge Reshape Valuation Debate - simplywall.st
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga
Self -Care for Caregivers - Pfizer
PFIZER INC : UBS is Neutral - marketscreener.com
GIPR antagonists reported in Pfizer patent - bioworld.com
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity - FinancialContent
Van ECK Associates Corp Sells 4,744,499 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE): Impact from BioNTech Partnership in 2026 - GuruFocus
Legal & General Group Plc Purchases 3,296,415 Shares of Pfizer Inc. $PFE - MarketBeat
Banque Cantonale Vaudoise Sells 92,252 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer, ASKA Pharma to co-promote RSV vaccine Abrysvo in Japan - BioSpectrum Asia
BMO Maintains Outperform on Pfizer (PFE) March 2026 - Meyka
Pfizer (PFE) Valuation Check After New Tilrekimig Phase 2 Success And Pipeline Progress - simplywall.st
Pfizer's payout ratio is still over 100%. Is a dividend cut inevitable? - MSN
Pfizer Tries Again In Atopic Dermatitis, This Time With A Trispecific - Citeline News & Insights
Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent - TechStock²
Pfizer's Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable? - Yahoo Finance
Pfizer Leans On Obesity And Immunology To Refresh Growth Story - Yahoo Finance
BMO reiterates Pfizer stock Outperform rating on antibody data - Investing.com
Pfizer (PFE) Advances Tilrekimig for Atopic Dermatitis with Posi - GuruFocus
Pfizer reports positive data from Phase 2 study for atopic dermatitis antibody (PFE:NYSE) - Seeking Alpha
Swiss National Bank Trims Stake in Pfizer Inc. $PFE - MarketBeat
562,908 Shares in Pfizer Inc. $PFE Bought by WINTON GROUP Ltd - MarketBeat
Pfizer’s tilrekimig meets Phase 2 trial endpoint for dermatitis - Investing.com
Pfizer (PFE) Reports Promising Results from Phase 2 Atopic Derma - GuruFocus
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study - Reuters
Pfizer shares dip despite positive trial results for skin condition drug - Investing.com Nigeria
Monthly Pfizer antibody improves atopic dermatitis, moves toward Phase 3 - Stock Titan
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):